Table 3

Incidence rates of events and HRs (95% CI) of medication groups for all events during 6 months’ follow-up

Number of eventsIncidence of event per 1 000 patient-yearsHR (95% CI)
EventPatient-yearsCrudeAdjusted*
Ischaemic heart disease
 NRT506141782.411
 Bupropion1721164.00.78 (0.43 to 1.42)1.18 (0.64 to 2.15)
 Varenicline175612872.90.89 (0.73 to 1.08)1.02 (0.83 to 1.24)
Stroke
 NRT514015530.211
 Bupropion175317.10.57 (0.18 to 1.79)0.62 (0.20 to 1.96)
 Varenicline17803419.10.63 (0.44 to 0.92)0.76 (0.52 to 1.11)
Heart failure
 NRT514811822.911
 Bupropion17515.70.25 (0.03 to 1.79)0.40 (0.06 to 2.89)
 Varenicline17831810.10.44 (0.27 to 0.72)0.56 (0.34 to 0.92)
Peripheral vascular disease
 NRT51569318.011
 Bupropion17515.70.32 (0.04 to 2.28)0.49 (0.07 to 3.56)
 Varenicline1784179.50.53 (0.32 to 0.89)0.62 (0.37 to 1.05)
Arrhythmia
 NRT513417433.911
 Bupropion174423.00.68 (0.25 to 1.83)0.92 (0.34 to 2.50)
 Varenicline17773821.40.63 (0.44 to 0.90)0.84 (0.59 to 1.20)
Depression
 NRT4989686137.511
 Bupropion1711799.40.72 (0.45 to 1.17)0.73 (0.45 to 1.18)
 Varenicline174516795.70.70 (0.59 to 0.83)0.73 (0.61 to 0.86)
Self-harm
 NRT5174367.011
 Bupropion17515.70.82 (0.12 to 6.00)0.90 (0.12 to 6.58)
 Varenicline178695.00.72 (0.35 to 1.51)0.78 (0.37 to 1.63)
  • *Adjusted for age, sex, socioeconomic status, Medical Research Council dyspnoea score, Strategic Health Authority of the general practice, comorbidities (ie, prior recordings of COPD, diabetes, peptic ulcer disease, renal disease, rheumatological disease or cancer), alcohol misuse and any recordings of the neuropsychiatric and cardiovascular events of interest that occurred before the patient's entry to the cohort.

  • NRT, nicotine replacement therapy.